Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 3,776–3,800 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
· Oncotarget · 2016 · PMID 26701727 · validated civic_curation pubmed
Upregulation of AKT3 Confers Resistance to the AKT Inhibitor MK2206 in Breast Cancer.
· Mol Cancer Ther · 2016 · PMID 27297869 · validated civic_curation pubmed
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
· Nat Commun · 2017 · PMID 28211448 · validated civic_curation pubmed
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
· Oncogene · 2014 · PMID 24141786 · validated civic_curation pubmed
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
· Clin Cancer Res · 2010 · PMID 20453058 · validated civic_curation pubmed
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
· Oncogene · 2008 · PMID 18408761 · validated civic_curation pubmed
ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.
· Haematologica · 2013 · PMID 23585524 · validated civic_curation pubmed

Showing 3,776–3,800 of 4,399 publications

← Previous
1
…
151
152
153
…
176
Next →

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

· J Clin Oncol · 2009 · PMID 19075254 · validated civic_curation pubmed

Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.

· Cancer Res · 2007 · PMID 17671205 · validated civic_curation pubmed

Identifying the determinants of response to MDM2 inhibition.

· Oncotarget · 2015 · PMID 25730903 · validated civic_curation pubmed

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

· Nature · 2015 · PMID 25970248 · validated civic_curation pubmed

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

· Cancer Res · 2017 · PMID 28490518 · validated civic_curation pubmed

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.

· Mol Cancer · 2013 · PMID 23497317 · validated civic_curation pubmed

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

· Cancer Res · 2010 · PMID 20551065 · validated civic_curation pubmed

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

· Cancer Discov · 2017 · PMID 28193778 · validated civic_curation pubmed

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

· Oncotarget · 2016 · PMID 27167191 · validated civic_curation pubmed

Drug-sensitive FGFR3 mutations in lung adenocarcinoma.

· Ann Oncol · 2017 · PMID 27998968 · validated civic_curation pubmed

Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.

· Oncotarget · 2015 · PMID 26528855 · validated civic_curation pubmed

Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer.

· PLoS One · 2012 · PMID 22808142 · validated civic_curation pubmed

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

· Cancer Res · 2008 · PMID 19010894 · validated civic_curation pubmed

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.

· Blood · 2013 · PMID 24081659 · validated civic_curation pubmed

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

· Cancer Discov · 2016 · PMID 27231123 · validated civic_curation pubmed

ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.

· Blood · 2018 · PMID 29880614 · validated civic_curation pubmed

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

· Nat Med · 2016 · PMID 27135738 · validated civic_curation pubmed

SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.

· Nat Commun · 2019 · PMID 30718506 · validated civic_curation pubmed